Product Description: Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer[1][2][3].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Vázquez AM, et al. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol. 2012 Oct 23;2:150. /[2]Gajdosik Z. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs Today (Barc). 2014 Apr;50(4):301-7. /[3]Segatori VI, et al. Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Front Oncol. 2012 Nov 8;2:160. /[4]Truong CS, et al. Oncolytic Vaccinia Virus in Lung Cancer Vaccines. Vaccines (Basel). 2022 Feb 4;10(2):240.
CAS Number: 946832-34-4
Molecular Weight: N/A
Compound Purity: 99.90
Research Area: Cancer; Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Others